News &amp; Updates

For pregnant women at risk of delivering preterm, intravenous administration of magnesium sulfate prior to preterm birth at 30–34 week of gestation does not appear to minimize the chances of child survival free of cerebral palsy at 2 years, as shown in a study.

Magnesium sulfate for women at risk of preterm birth does not reduce cerebral palsy risk

Does concomitant TKI‒SSRI use increase risk of bleeding, thrombotic events?

Patients with chronic myeloid leukaemia (CML) who are being treated with both tyrosine kinase inhibitors (TKIs) and selective serotonin reuptake inhibitors (SSRIs) do not appear to be at greater total risk of bleeding or thrombotic events than those on TKIs only, reveals a study. However, concomitant use of TKIs and SSRIs may elevate the risk of intracranial bleeding.

Does concomitant TKI‒SSRI use increase risk of bleeding, thrombotic events?

19 Aug 2023

Pimavanserin well tolerated in older patients with neurodegenerative disease

19 Aug 2023 by

Pimavanserin therapy was well tolerated in frail adult and older patients with neuropsychiatric symptoms related to neurodegenerative disease (NDD) in a recent study presented at AAIC 2023.

Pimavanserin well tolerated in older patients with neurodegenerative disease

Switching antiretroviral regimens does not help with weight loss

18 Aug 2023 by

Switching from an integrase inhibitor (INI)-based antiretroviral treatment (ART) regimen to a protease inhibitor (PI)-based regimen falls short of reversing weight gain while on the INI-based regimen, according to the results of the open-label phase IV DEFINE trial.

Switching antiretroviral regimens does not help with weight loss

Fezolinetant reduces menopause-related vasomotor symptoms

18 Aug 2023 by

Treatment with fezolinetant 30 and 45 mg daily provides relief from moderate-to-severe vasomotor symptoms (VSM) associated with menopause, suggests a study.

Fezolinetant reduces menopause-related vasomotor symptoms

18 Aug 2023

Radioactive iodine therapy helps prevent papillary thyroid cancer recurrence

Patients with unstimulated thyroglobulin (Tg) ≤1 ng/mL or stimulated Tg ≤10 ng/mL who receive radioactive iodine therapy (RAIT) may benefit from a lower recurrence risk of intermediate-risk papillary thyroid cancer (PTC), reveals a study.

Radioactive iodine therapy helps prevent papillary thyroid cancer recurrence

Oral contraceptive use not linked to CVD, all-cause death in women

Women who use oral contraceptives do not have an excess risk of cardiovascular disease (CVD) events and all-cause death, with the contraceptives potentially conferring benefits to those who have used them for longer, according to a study.

Oral contraceptive use not linked to CVD, all-cause death in women

Long-term hydrochlorothiazide use ups risk of skin cancer

Using hydrochlorothiazide (HCTZ) for longer durations and in higher cumulative doses increases the risks for keratinocyte carcinoma and melanoma, reveals a study.

Long-term hydrochlorothiazide use ups risk of skin cancer

17 Aug 2023

PPI exposure can make children susceptible to serious infections

The use of proton pump inhibitors (PPIs) appears to pose heightened risks of serious infections in young children, according to a study.

PPI exposure can make children susceptible to serious infections

Relugolix combo reduces dysmenorrhea, NMPP in premenopausal women

17 Aug 2023 by

The use of relugolix 40 mg in combination with oestradiol 1 mg and norethisterone acetate 0.5 mg (relugolix combination therapy [relugolix-CT]) significantly reduced dysmenorrhea and nonmenstrual pelvic pain (NMPP) in premenopausal women with endometriosis who received prior hormonal treatment, according to a post hoc analysis of two phase III trials presented at ESHRE 2023.

Relugolix combo reduces dysmenorrhea, NMPP in premenopausal women